Literature DB >> 7214345

Kinetic effects of sangivamycin in sarcoma 180 in vitro.

P S Ritch, R I Glazer, R E Cunningham, S E Shackney.   

Abstract

The lethal and sublethal effects of sangivamycin (SGM) were studied in sarcoma 180 in vitro in relation to drug concentration and duration of drug exposure. SGM lethality was found to be dependent on both drug concentration and duration of drug exposure. Pronounced effects on cell survival were observed only when SGM exposure was prolonged; with prolonged drug exposure, small increments in SGM concentration resulted in large increases in cell killing. Log-phase cells were more susceptible to the lethal effects of SGM than were early-plateau-phase cells. Measurements of incorporation of [3H]thymidine and [3H]uridine into the acid-insoluble cell fraction demonstrated inhibition of both DNA and RNA synthesis by SGM which was also dependent on drug concentration and duration of drug exposure, reflecting the lethality characteristics of SGM. As SGM concentration was increased, DNA synthesis was inhibited more rapidly than was RNA synthesis. Flow cytometry demonstrated a concentration- and time-dependent accumulation of cells in the late S and G2-M region of the DNA histogram. Our findings indicate that maximum lethality is obtained by prolongation of SGM exposure, and they suggest that pharmacokinetic studies may be important for determining regimens which provide such exposure in humans.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7214345

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Antagonism of the cytotoxic but not antiviral effects of ara-sangivamycin by adenosine.

Authors:  G M Birch; S H Krawczyk; L B Townsend; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.

Authors:  Donghwa Kim; Mei Sun; Lili He; Qing-Hua Zhou; Jun Chen; Xia-Meng Sun; Gerold Bepler; Said M Sebti; Jin Q Cheng
Journal:  J Biol Chem       Date:  2010-01-12       Impact factor: 5.157

3.  A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.

Authors:  Ryan P Bennett; Courtney L Finch; Elena N Postnikova; Ryan A Stewart; Yingyun Cai; Shuiqing Yu; Janie Liang; Julie Dyall; Jason D Salter; Harold C Smith; Jens H Kuhn
Journal:  Viruses       Date:  2020-12-31       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.